Thymosin Alpha-1

Thymosin alpha 1 is a peptide naturally occurring in the thymus that has long been recognized for modifying, enhancing, and restoring immune function.

Key Benefits

• May support healthy immune system function and immune response regulation
• Commonly researched for enhancing the body’s defense against infections and illness
• May help support recovery by promoting balanced immune activity
• Research suggests potential benefits for healthy aging, inflammation management, and overall immune resilience

FDA-Approved Uses

Thymosin Alpha-1 (Thymalfasin; brand name Zadaxin®) has a unique and often-misunderstood regulatory standing in the United States:

FDA Status:

• FDA Orphan Drug Designation: Granted for multiple conditions (malignant melanoma, chronic active hepatitis B, DiGeorge anomaly with immune defects, hepatocellular carcinoma)
• Orphan Drug Designation ≠ FDA Drug Approval
• Zadaxin is NOT commercially marketed or sold in the USA
• Available in the USA under Expanded Access (Compassionate Use) protocols for qualifying patients
• 503A Category 1: Thymosin Alpha-1 IS on the FDA 503A Bulks List — it CAN be legally compounded by licensed 503A compounding pharmacies with a valid physician prescription

Approved in 35+ countries (NOT USA) including:

• China, Italy, Philippines, Russia, South Korea, Argentina, and others
• Approved indications internationally: Chronic hepatitis B, chronic hepatitis C (combination with interferon), malignant melanoma (adjuvant), immunomodulation in cancer, DiGeorge syndrome, and COVID-19 immune support (China, emergency approval 2020)

FDA-recognized orphan indications:

1. Malignant melanoma (adjuvant immunotherapy)
2. Chronic active hepatitis B (monotherapy or with interferon)
3. DiGeorge anomaly with immune defects
4. Hepatocellular carcinoma

Additional conditions studied in clinical trials (off-label / investigational):

1. Chronic hepatitis C (with interferon alpha)
2. HIV/AIDS (immune reconstitution)
3. Non-small cell lung cancer
4. Chemotherapy-induced immune suppression recovery
5. Sepsis (immune paralysis in ICU — large China COVID-19 trials)
6. COVID-19 (extensive Chinese RCT evidence; not FDA-reviewed)
7. Vaccine immune response enhancement (elderly, hemodialysis patients)
8. Immunosenescence reversal in aging

Trade Names in USA and Manufacturers

No FDA-approved commercial brand available in USA.

International brand:
– Zadaxin® (thymalfasin for injection 1.6 mg) — SciClone Pharmaceuticals
Original developer: Alpha-1 Biomedical / Sciclone Pharmaceuticals (San Mateo, CA, USA)
[Note: Sciclone developed Zadaxin but commercialized it primarily in Asia — primarily China, Italy, and 35+ countries]
Each vial: 1.6 mg lyophilized thymalfasin + 50 mg mannitol + sodium phosphate buffer (pH 6.8)
Reconstituted with 1 mL sterile water for injection → 1.6 mg/mL

US availability:
– Licensed 503A compounding pharmacies: LEGAL with valid physician prescription (Category 1 status)
– Compounded thymosin alpha-1 is widely available through US longevity and integrative medicine clinics
– Imported Zadaxin (personal use, grey area): Technically possible through international online pharmacies
– Not available at standard US retail pharmacies (not commercially marketed in USA)

Molecular identity:
– Synthetic 28-amino acid peptide (thymalfasin)
– Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
– N-terminally acetylated (Ac- at Ser position 1)
– MW: 3,108 Daltons
– Derived from: prothymosin alpha (113-amino acid precursor protein); Tα1 = residues 1–28
– Original source: Calf thymus gland; now produced by total chemical synthesis

Dosage

Based on Zadaxin international prescribing information and clinical trial protocols:

Hepatitis B (standard Zadaxin protocol):
Dose: 1.6 mg SC twice weekly
Duration: 6–12 months
Schedule: Two injections per week, any two consistent days
Reconstitute immediately before administration

Compounded TA-1) — cancer support / immune modulation:
Dose: 1.6 mg SC 2–3 times per week
Duration: 4–12 weeks (varies by indication and response)
Monitoring: CBC, lymphocyte counts, immunoglobulin levels

Off-label — Vaccine enhancement (immune compromised / elderly):
1.6 mg SC on day of vaccination + repeat dose 3–7 days later

Off-label — Sepsis/ICU (based on Chinese trial protocols):
1.6 mg SC or 3.2 mg SC twice daily for 5–7 days
(Higher doses studied in Chinese COVID-19 and sepsis trials)

Anti-aging / immune restoration (longevity clinics):
1.6 mg SC once or twice weekly
Cycles of 4–8 weeks, 1–3 times per year

Reconstitution:
Add 1 mL Sterile Water for Injection to lyophilized 1.6 mg vial
Administer immediately after reconstitution
Do not store reconstituted solution

Pricing

Compounded Thymosin Alpha-1 (503A pharmacy, legal with prescription):
Per vial (1.6 mg): ~15–15–40
Monthly cost (2x/week protocol): ~120–120–320/month
Monthly cost (3x/week): ~180–180–480/month

Imported Zadaxin (international brand):
Per vial: ~15–15–30 (from Asian/Eastern European sources)
Monthly cost: ~120–120–240/month

US telehealth longevity/integrative clinics:
~150–150–400/month including physician consultation and compounded supply

Note: TA-1 pricing is higher per month than simpler peptides due to longer amino acid chain (28 AA) requiring more complex synthesis — but it remains affordable relative to branded biologics.

Most access is cash-pay via 503A compounding with physician prescription.

Tips

• TA-1 is Category 1 — it CAN be legally prescribed and compounded by licensed 503A pharmacies in the USA. Unlike many research peptides in this document series, TA-1 has a legitimate, legal, physician-supervised access pathway right now.
• For patients with hepatitis B or C, cancer, or significant immunosuppression: TA-1 has the strongest and most extensive clinical evidence base of any peptide in this document series, with 35+ country approvals and decades of human safety data.
• COVID-19 use: Extensive Chinese RCT evidence showed TA-1 reduced mortality and improved recovery in severe COVID-19 through immune modulation.
• Vaccine enhancement: Studies show TA-1 significantly improves vaccine immunogenicity in elderly patients and those with impaired immune response (hemodialysis patients, cancer patients).
• IMPORTANT: TA-1 is an IMMUNE ENHANCER — patients on immunosuppressive therapy (organ transplants, autoimmune disease medications like prednisone, methotrexate, biologics) should discuss with their physician, as enhanced immune activity may increase rejection or autoimmune flare risk.
• TA-1 is NOT a stimulant, not a hormone, and does not affect GH, cortisol, IGF-1, or reproductive hormones. Its activity is specific to immune cell maturation and activation pathways.

Side Effects

One of the best-characterized safety profiles of any peptide in this document series — supported by decades of clinical use and formal trials in 35+ countries.

From Zadaxin prescribing information and pooled clinical trial data:

Most patients experience NO adverse effects:
– The most consistent finding across TA-1 clinical trials is excellent tolerability comparable to placebo in most participants

Commonly reported (mild, generally transient):

• Injection site reactions: Mild redness, swelling, or discomfort at SC injection site (most common — local, transient)
• Flu-like symptoms: Mild fever, fatigue, malaise — particularly early in treatment; reflects immune activation
• Headache (mild; uncommon)
• Nausea (mild; uncommon)

Less common:
– Transient elevation of liver enzymes: Observed in some hepatitis patients; may reflect immune-mediated liver inflammation (clinical vigilance required)

Important safety advantages:

• No serious adverse events attributable to TA-1 reported across major clinical trials
• No hormonal disruption
• No organ toxicity documented at standard doses
• No dependence, tolerance, or withdrawal
• Used safely in elderly, immunocompromised, and cancer patients in large trials

Organ transplant / autoimmune caution:
– TA-1 enhances Th1 immune activity and T-cell function
– In organ transplant recipients: Could increase rejection risk
– In autoimmune disease: Could potentially worsen immune-mediated conditions
– Requires careful physician assessment before use in these populations

Contraindications

Per Zadaxin international prescribing information:

Contraindicated:
– Known hypersensitivity to thymalfasin or any excipient in the formulation

Use with extreme caution:

• Organ transplant recipients on immunosuppressive therapy: TA-1 enhances immune activity — theoretical risk of graft rejection; discuss with transplant specialist
• Active autoimmune disease (rheumatoid arthritis, SLE, multiple sclerosis, etc.): Enhanced Th1 immune activation may exacerbate autoimmune conditions in susceptible patients; physician assessment required

Use with caution:
– Pregnancy: Zadaxin prescribing information states ‘If you are pregnant only take Zadaxin if clearly needed’ — animal safety data limited; physician judgment required
– Breastfeeding: Exercise caution — thymalfasin safety in nursing not established
– Pediatric use: Safety and efficacy not established in children per Zadaxin label

Notable absence of typical contraindications:
– NOT contraindicated in cancer patients (in fact, studied and approved for cancer immunotherapy)
– NOT contraindicated in elderly (used extensively in aging and immune senescence studies)
– NOT contraindicated in HIV/AIDS patients (studied for immune reconstitution)

Pharmacology

Thymosin Alpha-1 (thymalfasin; Tα1) is a synthetic 28-amino acid polypeptide identical to the naturally occurring N-terminal fragment of prothymosin alpha, a 113-amino acid protein produced by the thymus gland. The peptide is N-terminally acetylated at serine position 1, which is critical for biological activity. MW: 3,108 Daltons. Originally isolated from calf thymus tissue in 1972 by Allan Goldstein’s laboratory at George Washington University — the same group that discovered the broader thymosin family of peptides. Tα1 is the most clinically studied thymic peptide.

In human physiology:
– Thymosin alpha-1 is naturally produced and secreted by thymic epithelial cells
– Acts as a thymic hormone — directing T-lymphocyte maturation and immunological education
– Endogenous Tα1 levels decline with age (thymic involution) and in immunocompromised states
– Exogenous Tα1 (thymalfasin) restores immune competence by mimicking thymic hormonal signaling

Manufacturing: Produced by solid-phase chemical synthesis from defined amino acids (not extracted from biological tissue). Formulated as sterile lyophilized powder for reconstitution with 1 mL sterile water. pH adjusted to 6.8 with sodium phosphate buffer. 50 mg mannitol added as stabilizer/bulking agent.

Mechanism of action

Thymosin Alpha-1 exerts immunomodulatory effects through multiple interconnected immune pathways:

1. Toll-Like Receptor (TLR) Activation — Primary innate immune mechanism:
Tα1 activates TLR2 and TLR9 on plasmacytoid dendritic cells (pDC)

• Triggers innate immune signaling cascade
• Promotes dendritic cell maturation and antigen-presenting capability
• Induces production of type I interferons (IFN-α/β) — antiviral and anti-tumor signaling

2. T-Cell Maturation and Activation:

• Promotes differentiation of naive T-cells into mature, functional CD4+ and CD8+ T-lymphocytes
• Enhances T-cell proliferation and survival
• Upregulates IL-2 receptor expression on T-cells (increasing IL-2 responsiveness)
• Promotes production of Th1 cytokines: IFN-γ, IL-2 (cell-mediated immunity)

3. NK Cell Enhancement:

• Increases natural killer (NK) cell number and cytolytic activity
• Enhances tumor cell and virally-infected cell killing

4. Regulatory T-Cell (Treg) Modulation:

• In immunocompromised states: Reduces excessive immunosuppression by modulating Tregs
• In autoimmunity (theoretical): May restore immune balance by normalizing Treg function

5. Dendritic Cell Maturation: Promotes maturation of immature dendritic cells → more effective antigen presentation → stronger adaptive immune response

6. Anti-Tumor Mechanisms:

• Increased NK cell activity + enhanced CD8+ cytotoxic T-cell function → tumor cell killing
• Increased IFN-γ production → anti-proliferative effects on tumor cells

Result Claims By Different Companies

SciClone Pharmaceuticals / Alpha-1 Biomedical (based on clinical trial data):

Hepatitis B (pooled analysis of 3 RCTs, n=223 patients):
– Zadaxin 1.6 mg SC twice weekly for 6–12 months
– Demonstrated significantly higher HBeAg seroconversion rates vs. placebo
– Improved ALT normalization and HBV DNA suppression
– Supported regulatory approvals in 35+ countries

COVID-19 (Chinese RCTs, 2020–2021):
– Multiple Chinese hospital-based RCTs: TA-1 added to standard COVID-19 treatment reduced mortality in severe/critical cases
– Mechanism: restored adaptive immune response in patients with lymphopenia and immune exhaustion
– Used under emergency authorization in China; not FDA-reviewed

Cancer immunotherapy:
– Approved as adjuvant in malignant melanoma (Italy) and hepatocellular carcinoma (multiple countries)
– Phase 2 trials: Non-small cell lung cancer — improved response rates and survival when combined with chemotherapy in Chinese trials

Vaccine enhancement:
– Carraro et al. (Vaccine, 2012): TA-1 significantly enhanced immune response to pandemic H1N1 influenza vaccine in hemodialysis patients
– Multiple studies: Improved seroconversion rates in elderly patients with impaired vaccine responses

Anti-aging / immune senescence:
– Multiple small studies: TA-1 reversed age-related decline in T-cell function in older adults
– Generally well-tolerated across all patient populations studied

Disclaimer

This content about “Thymosin Alpha-1” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.